Anti-biofilm properties of the antimicrobial peptide temporin 1Tb and its ability, in combination with EDTA, to eradicate Staphylococcus epidermidis biofilms on silicone catheters by Maisetta, Giuseppantonio et al.
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=gbif20
Download by: [Università di Pisa] Date: 30 June 2016, At: 03:33
Biofouling
The Journal of Bioadhesion and Biofilm Research
ISSN: 0892-7014 (Print) 1029-2454 (Online) Journal homepage: http://www.tandfonline.com/loi/gbif20
Anti-biofilm properties of the antimicrobial
peptide temporin 1Tb and its ability, in
combination with EDTA, to eradicate
Staphylococcus epidermidis biofilms on silicone
catheters
Giuseppantonio Maisetta, Lucia Grassi, Mariagrazia Di Luca, Silvia
Bombardelli, Chiara Medici, Franca Lisa Brancatisano, Semih Esin &
Giovanna Batoni
To cite this article: Giuseppantonio Maisetta, Lucia Grassi, Mariagrazia Di Luca, Silvia
Bombardelli, Chiara Medici, Franca Lisa Brancatisano, Semih Esin & Giovanna Batoni
(2016) Anti-biofilm properties of the antimicrobial peptide temporin 1Tb and its ability, in
combination with EDTA, to eradicate Staphylococcus epidermidis biofilms on silicone catheters,
Biofouling, 32:7, 787-800, DOI: 10.1080/08927014.2016.1194401
To link to this article:  http://dx.doi.org/10.1080/08927014.2016.1194401
Published online: 28 Jun 2016.
Submit your article to this journal 
View related articles 
View Crossmark data
is the polysaccharide intercellular adhesin (PIA), a poly-
mer of β-1,6-linked N-acetyl-glucosamine with partially 
N-deacetylated amine groups, synthesized and secreted by 
the gene products of the ica operon, icaA, icaD, icaB and 
icaC (Fey & Olson 2010). Ica-negative clinical isolates of 
S. epidermidis, exhibiting a marked biofilm-forming ability, 
have also been described (Kogan et al. 2006; Brancatisano 
et al. 2014). Biofilm accumulation in these isolates seems 
to be protein-mediated as their biofilms are sensitive 
to protease treatment, but resistant to polysaccharide- 
degrading enzymes (Kogan et al. 2006; Brancatisano et al. 
2014). It is well known that cells in biofilms are intrinsi-
cally refractory to antimicrobial drugs (Høiby et al. 2010). 
This is due to several factors that include: (1) the over-
all low growth rate of cells in biofilms, (2) the presence 
of the extracellular matrix that hampers the diffusion of 
antibacterial compounds through the biofilm layers, (3) 
the presence of ecological niches with low oxygen and 
nutrient concentrations that favor cells entering into a 
dormant state (‘persisters’), and (4) the facility in exchang-
ing mobile genetic elements carrying resistance genes, due 
to cell vicinity. The growing use of medical devices and 
Introduction
The colonization of medical devices such as intravascular 
catheters, urinary catheters and orthopedic implants by 
microorganisms able to form biofilms is at present a seri-
ous health-care problem.
Staphylococcus epidermidis is one of the major noso-
comial pathogens, often associated with biofilm-related 
medical device infections (Gomes et al. 2014). It is gener-
ally agreed that S. epidermidis biofilms develop in at least 
four sequential phases (Fey & Olson 2010): after an initial 
adhesion phase, which is typically measured in vitro after 
1–2-h exposure to a surface, attached cells form small clus-
ters or ‘microcolonies’ with biofilm-like properties (accu-
mulation phase). In the presence of appropriate nutritional 
conditions microcolonies grow to form a mature biofilm 
(maturation phase) that usually acquires a characteristic 
3-D architecture within 18–24 h of in vitro growth. A final 
dispersal phase limits biofilm expansion and involves the 
detachment of cells from the biofilm that, in vivo, may lead 
to dissemination of infection to surrounding tissues or to 
the blood. The best studied component of the extracellu-
lar polymeric substance (EPS) of staphylococcal biofilms 
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ABSTRACT
In search of new antimicrobials with anti-biofilm potential, in the present study activity of the frog-
skin derived antimicrobial peptide temporin 1Tb (TB) against Staphylococcus epidermidis biofilms 
was investigated. A striking ability of TB to kill both forming and mature S. epidermidis biofilms was 
observed, especially when the peptide was combined with cysteine or EDTA, respectively. Kinetics 
studies demonstrated that the combination TB/EDTA was active against mature biofilms already 
after 2–4-h exposure. A double 4-h exposure of biofilms to TB/EDTA further increased the therapeutic 
potential of the same combination. Of note, TB/EDTA was able to eradicate S. epidermidis biofilms 
formed in vitro on silicone catheters. At eradicating concentrations, TB/EDTA did not cause hemolysis 
of human erythrocytes. The results shed light on the anti-biofilm properties of TB and suggest a 
possible application of the peptide in the lock therapy of catheters infected with S. epidermidis.
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The present study focuses on the anti-biofilm prop-
erties of temporin 1Tb (TB), a frog skin-derived AMP 
previously shown to exert potent antibacterial properties 
against clinically relevant bacterial species in planktonic 
form (Mangoni et al 2008). The possibility of improving 
the anti-biofilm potential of TB by combining the peptide 
with Cys or EDTA was also investigated.
A striking ability of TB to kill both forming and mature 
S. epidermidis biofilms was observed, especially when 
the peptide was used in combination with Cys or EDTA, 
respectively. Interestingly, TB in combination with EDTA 
was able to eradicate S. epidermidis biofilms formed in 
vitro on silicone catheters, suggesting the possible use of 
TB-combinatorial strategies in the lock therapy of central 
venous access devices colonized by S. epidermidis biofilms.
Materials and methods
S. epidermidis strains
Three clinical isolates of S. epidermidis (Se30, SeBER, 
SeVIC) and the reference strain ATCC 35,984 were used 
in the study. All the strains have been previously char-
acterized in detail with respect to their drug susceptibil-
ity profile, biofilm forming ability, site of isolation and 
the nature of the biofilm EPS (Brancatisano et al. 2014). 
The main characteristics of the strains are summarized 
in Table 1. The strains were grown in tryptone soy broth 
(TSB) (Oxoid, Basingstoke, UK) supplemented with 0.25% 
glucose (TSB/Glc) overnight at 37°C or on Tryptone soy 
agar (TSA) (Oxoid for 24 h at 37°C for colony-forming 
unit (CFU) determination.
TB and other antimicrobial compounds
Synthetic TB (LLPIVGNLLKSLL-NH2) (purity > 98%) 
was purchased from the Peptide Specialty laboratories 
GmBH (Heidelberg, Germany). The peptide was diluted 
in milli-Q water to obtain a stock solution of 2 mg ml−1 
and kept frozen at −80°C until use. Disodium EDTA 
and L-cysteine (Cys) were obtained from Sigma Aldrich 
the consequent increment in biofilm-associated infections 
indicate the urgent need to identify new drugs active 
against microbial biofilms.
Over the last few years, antimicrobial peptides (AMPs) 
have been proposed as a new source of anti-biofilm agents 
as they display several features suitable for targeting cells 
in the biofilm mode of growth (Batoni et al. 2016). An 
updated list of AMPs displaying activity against biofilms 
of clinically relevant microorganisms is freely available 
at www.baamps.it (Di Luca et al. 2015). Most AMPs have 
shown promise in preventing biofilm formation, while 
molecules able to treat mature biofilms are only rarely 
reported and intensive research to design AMPs with 
optimized anti-biofilm properties or to improve further 
the activity of existing AMPs is highly desirable. In this 
respect, AMP-based anti-biofilm strategies aimed at com-
bining AMPs with synergistic compounds may represent a 
good, but still relatively poorly investigated approach. The 
combination of conventional and unconventional anti-
microbial compounds with AMPs may improve both the 
prophylactic and the therapeutic efficacy of some AMPs 
by preventing the insurgence of resistance or by lowering 
the drug dosage and, thus, reducing the possible toxic 
side effects. Furthermore, the heterogeneity of micro-
bial biofilms makes combinatorial strategies particularly 
attractive, as there might be the need to target cells in 
different metabolic states or in different environmental 
niches. Possible combinatorial strategies include the use 
of AMPs with: (1) conventional antibiotics (Maisetta 
et al. 2009; Mataraci & Dosler 2012), (2) compounds that 
dissolve and/or digest the biofilm matrix or inhibit its 
synthesis (Chaignon et al. 2007; Donelli et al. 2007; Wu 
et al. 2011), and (3) inhibitors of quorum sensing, the 
bacterial communication machinery often involved in 
biofilm formation (Brackman & Coenye 2015). Among 
these strategies, one of the most promising is the use of 
compounds that affect the biofilm extracellular matrix 
in synergy with bactericidal agents in order to facilitate 
the targeting of microorganisms entrapped in the matrix 
(Chaignon et al. 2007; Donelli et al. 2007; Kaplan et al. 
2012). In this regard, it has been reported that sulfhydryl 
compounds, including L-cysteine (Cys), inhibit staphylo-
coccal biofilm formation by inhibiting PIA biosynthesis 
(Wu et al. 2011). It is also known that metal cations (cal-
cium, magnesium, iron) may be involved in maintaining 
the structure of the biofilm extracellular matrix and that 
chelating agents like ethylenediaminetetra-acetic acid 
(EDTA) may destabilize the biofilm structure (Banin et al. 
2006). EDTA is also endowed with antimicrobial proper-
ties and has been used with success in combination with 
antibiotics against biofilms of a variety of clinical strains 
(Lebeaux et al. 2015).
Table 1.  Main features of the S. epidermidis strains used in the 
study.
aPolysaccharide intercellular adhesion.
bPiA-negative strains had an extracellular matrix made mainly of proteins 
(Brancatisano et al. 2014).
S. epidermidis 
strain
Isolation 
site Biofilm forming ability
PIAa-producing 
ability
ATCC 35,984 Catheter Strong biofilm producer PiA-positive
Se30 Catheter Strong biofilm producer PiA-positive
SeBER Catheter Moderate biofilm producer PiA-negativeb
SeViC Blood Strong biofilm producer PiA-negative
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(St Louis, MO, USA). A stock solution of 0.5-M EDTA was 
prepared by adjusting the pH to 8.0 with NaOH. This solu-
tion was then diluted to 50-mM (18.6 mg ml−1) in milli-Q 
water to obtain the working solution. A stock solution of 
400-mM Cys was prepared in milli-Q water. Both solu-
tions were dispensed into aliquots and stored at −20°C.
Determination of the minimum inhibitory 
concentration (MIC) of TB, Cys and EDTA against 
planktonic bacteria in biofilm-like conditions
The MIC values for TB, Cys and EDTA against planktonic 
S. epidermidis cells were evaluated by the microdilution 
method in the same experimental conditions used 
thereafter for the biofilm assays. To this end, stationary 
phase S. epidermidis cells, obtained from cultures grown 
overnight, were diluted 1:100 in biofilm promoting 
medium (BPM, see next paragraph). Aliquots of 90  μl 
of bacterial suspensions were incubated for 24  h at 
37°C in polypropylene tubes in the presence of TB at 
concentrations ranging from 6.25 to 100 μg ml−1, Cys from 
78 to 2,500 μM, or EDTA from 0.125 to 32 mg ml−1, in a 
final volume of 100 μl. The MIC values were determined 
as the lowest concentrations of the different compounds 
at which no bacterial growth was visible.
Biofilm inhibition assay by TB
S. epidermidis strains were cultured overnight in TSB/Glc 
at 37°C with shaking. Bacterial suspensions were diluted 
1:100 in BPM (TSB diluted 1:1 with 10-mM sodium phos-
phate buffer at pH 6.6 [SPB], with added glucose at 0.25%). 
A volume of 90 μl of each diluted bacterial suspension was 
dispensed into flat-bottom polystyrene 96-well microtiter 
plates (Corning Costar, Lowell, MA, USA) and 10 μl of TB 
solution were added to reach final peptide concentrations 
ranging from 12.5 to 50 μg ml−1. Wells without peptide 
were set up as positive controls. Plates were incubated at 
37°C without shaking for 24 h. At the end of the incu-
bation period, biofilm biomass was assessed by crystal 
violet (CV, bioMérieux, Firenze, Italy) staining as previ-
ously described (Brancatisano et al. 2014). In parallel, to 
evaluate the viable biofilm-embedded bacteria, cells were 
mechanically detached from biofilms at the end of the 
incubation period by means of a pipette tip, vigorously 
vortexed, serially diluted 10-fold, and finally plated on 
TSA. The number of CFU per well was determined after 
incubation of the plates at 37°C for 24 h. The assays were 
performed in triplicates, and the results expressed as the 
percentage biofilm biomass reduction compared with 
wells without peptide or as Log10 CFU ml−1 ± the stand-
ard error of the mean (SEM).
Biofilm treatment assays by TB
Biofilms of the four different S. epidermidis strains were left 
to form in 96 well plates for 24 h in BPM in the absence of 
TB or other antimicrobials. After repetitive washing with 
SPB to remove planktonic cells, established biofilms were 
treated with 50 or 100 μg ml−1 TB in a final volume of 
100 μl BPM. After 24-h incubation, biofilms were washed 
again with SPB and bacterial cells were mechanically 
removed by scraping with pipette tips and vigorous vor-
texing. To determine the number of viable bacteria surviv-
ing the treatment, 10-fold dilutions were plated onto TSA. 
The results were expressed as number of Log10 CFU ml−1 
obtained in at least three independent experiments ± SEM.
Combination studies
The possibility of improving the anti-biofilm potential of 
TB was investigated by combining the peptide with Cys 
or EDTA against forming or mature biofilms of two arbi-
trarily chosen strains of S. epidermidis, representative of 
PIA-positive (ATCC 35,984) and PIA-negative (SeVIC) 
strains, respectively. Biofilm inhibition assays were car-
ried out by co-incubating bacterial cells, prepared as 
described above, with sub-inhibitory concentrations of 
TB (range 6.25–25 μg ml−1) and different concentrations 
of Cys (range 39–1,250-μM) or EDTA (range 1.5–12 μg 
ml−1). After 24-h incubation, the total biofilm biomass 
was evaluated by CV staining and the results expressed 
as percentage biofilm biomass reduction compared to the 
control wells (bacteria incubated in medium only).
The ability of TB, in combination with EDTA or Cys to 
treat mature biofilms was assessed by exposing 24 h-old 
biofilms of the two representative S. epidermidis strains to 
sub-inhibitory concentrations of TB (range 25–100 μg ml−1) 
and different concentrations of Cys (range 10–40-mM) or 
EDTA (range 2–8 mg ml−1). Following incubation, the anti-
biofilm effect was evaluated in terms of biofilm-associated 
viable counts as described previously.
Among all the combinations tested, in both biofilm inhi-
bition and biofilm treatment assays, only the most powerful 
combinations, in terms of a reduction in biofilm biomass or 
viable count respectively, are shown in the ‘Results’ section.
Evaluation of the kinetics of the anti-biofilm effect 
of TB combined with EDTA against mature biofilms
The kinetics of the anti-biofilm effect of TB combined 
with EDTA were evaluated against established biofilms 
of the S. epidermidis ATCC 35,984. To this aim, 24 h-old 
biofilms were exposed for 2, 4 and 24 h to the TB-EDTA 
combination (100 μg ml−1 TB, 4 mg ml−1 EDTA) and the 
number of viable biofilm-associated cells determined as 
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then washed and resuspended in SPB pH 7.4 at a concen-
tration of 107 CFU ml−1. An aliquot of 10 μl of the bacte-
rial suspension was mixed with 90 μl of SPB containing 
increasing peptide concentrations ranging from 6.25 to 
50 μg ml−1 and 1% TSB. The bacteria-peptide suspensions 
were incubated for 4 h at 37°C with continuous rotation, 
serially diluted and plated on TSA for CFU counting. In 
parallel, S. epidermidis ATCC 35,984 cells were obtained 
from 24 h-old biofilms by mechanical detachment with 
a pipette tip and vigorous vortexing. Bacterial cells were 
re-suspended in SPB with 1% TSB, exposed to different 
concentrations of TB, and enumerated on TSA plates fol-
lowing the same procedure described above.
Eradication assay of S. epidermidis biofilms 
obtained on segments of silicone catheters after 
sequential exposures to TB in combination with 
EDTA
Overnight S. epidermidis ATCC 35,984 cultures were 
diluted 1:1,000 in fresh BPM. A volume of 200  μl was 
transferred to wells of 96-well plates containing sterile sil-
icone catheter segments (length 3 mm, diameter 4 mm; 
Teflex Medical, Monza-Brianza, Italy). The plates were 
incubated at 37°C for 24 h in static conditions to allow 
biofilms to form. At the end of the incubation period, the 
catheter segments were transferred into new wells and 
washed three times with 200μ μl of SPB. The catheters 
were moved again into new wells containing TB (50 or 
100 μg ml−1), EDTA (4 mg ml−1) or both in a final volume 
of 200μ μl of SPB. Wells containing catheter segments in 
SPB alone were set up as controls. Following a 4-h incu-
bation at 37°C with agitation, the treated and un-treated 
catheters were washed three times with SPB and incubated 
for an additional 4 h as before. The catheter segments were 
then transferred into new wells, washed three times with 
200 μl SPB and placed in propylene tubes containing 1 ml 
of SPB. One set of catheter segments was vigorously vor-
texed for 10 s, sonicated for 10 min in a water bath soni-
cator (45 kHz and 80 Watt, WWR, Radnor, PA, USA) and 
vortexed again for 10 s to dislodge biofilm forming bac-
teria. The bacterial suspensions so obtained were serially 
diluted and plated on TSA for CFU counts. Another set 
of catheter segments was not subjected to the dislodging 
procedure, but immediately placed into tubes containing 
1 ml of fresh TSB. In this case, after incubation for 72 h 
at 37°C with agitation, bacterial growth was evaluated by 
visual examination of the turbidity of the cultures.
Hemolysis assay
The hemolytic activity of TB was evaluated by deter-
mining at OD450 the amount of hemoglobin released 
reported above. In some experiments, the numbers of 
viable bacteria in the supernatants of biofilms treated 
with the combination or incubated in medium only were 
also evaluated. The effect of two consecutive exposures 
to the TB/EDTA combination on the number of residual 
cells was also assessed by exposing 24 h-old biofilms of 
S. epidermidis ATCC 35,984 to the combination for 4 h, 
washing with SPB, and again exposing the biofilms to the 
fresh combination for a further 2 or 4 h. Following wash-
ing and harvesting of the biofilm cells, the CFU number 
was assessed by plating serial dilutions of the bacterial 
suspensions onto TSA plates, as described previously.
Confocal laser scanning microscopy (CLSM) and 
image analyses
For biofilm CLSM study, S. epidermidis ATCC 35,984 was 
prepared as reported above. Briefly, 200 μl of 1:100 diluted 
overnight bacterial suspensions were dispersed into the 
inner wall of a glass bottom dish (WillCo GWSt-3512 
Wells BV, Amsterdam, The Netherlands) and incubated 
at 37°C. After 24 h, biofilms were washed three times with 
200 μl of 10-mM SPB (pH 6.6) and incubated with or with-
out the TB/EDTA combination (100 μg ml−1 TB, 4 mg ml−1 
EDTA) for 4  h. After three washes with SPB a second 
treatment was performed.
Biofilm cell viability after the TB/EDTA treatment was 
determined by staining cells with Syto9 and propidium 
iodide (PI) using the LIVE/DEAD BacLight Bacterial 
Viability Kit (Molecular Probes, Life technologies) as 
recommended by the manufacturer. After staining, the 
wells were rinsed three times with 200 μl of SPB, before 
capturing images. Stained biofilms were examined under 
a Leica CLSM (TCS SP5, Leica, Heidelberg, Germany) 
using a 63 × /1.2 NA water immersion objective (Leica 
Microsystems). The pinhole aperture was set to 1.0 Airy. 
Each sample was sequentially excited at 488 (Syto9) and 
561 (PI) nm and emissions were monitored at 500–540 and 
600–650 nm, respectively. For each condition, two inde-
pendent biofilms were analyzed. Images were acquired 
with 512 × 512 pixel resolutions in at least four different 
regions by collecting XY plans at different distances from 
the bottom of the biofilm (Petri glass). For each sample, 
different Z-plan images were also collected. All acquired 
data were processed and analyzed by ImageJ software ver-
sion 1.37 (NIH Image; http://rsbweb.nih.gov/ij/).
Killing activity of TB against S. epidermidis cells 
recovered from exponentially growing cultures or 
from 24 h-old biofilms
S. epidermidis ATCC 35,984 was cultured to mid-log phase 
in TSB for 3 h at 37°C with shaking. Bacterial cells were 
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The ability of TB to inhibit biofilm formation was 
evaluated by CV staining after incubation of S. epidermidis 
strains for 24 h with different concentrations of the peptide. 
As shown in Figure 1a, a striking ability of TB to reduce 
the biomass of forming biofilms of both PIA-positive and 
PIA-negative strains was observed, compared to cells 
from a 4% suspension of fresh human red blood cells 
(RBCs) exposed to different concentrations of the pep-
tide. To this aim, human RBCs from healthy volunteers 
were harvested by centrifuging venous blood at 1,700 
× g for 10 min at room temperature. After discarding 
the buffy coat layer, the RBC pellet was washed three 
times in PBS and diluted to 8% (v/v) in PBS. Aliquots 
of the 8% RBC solution (100  μl) were transferred in 
triplicates into wells of a 96-well microtiter plate and 
mixed with 100  μl of TB solutions at concentrations 
ranging from 6.25 to 320 μg ml−1. RBCs incubated in 
PBS served as negative controls, while RBCs incubated 
in 0.2% Triton X-100 (Sigma) were used as positive con-
trols (100% lysis). The microtiter plate was incubated at 
37°C for 60 min and centrifuged at 1,000 × g for 20 min 
at 4°C. The supernatant (100 μl) was then transferred to 
a new plate and the OD450 was measured in a microtiter 
plate reader. The percentage hemolysis was calculated 
according to the following formula: [(OD450 in the pep-
tide suspension − OD450 of the negative control in PBS)/
(OD450 of the positive control − OD450 of the negative 
control in PBS)] × 100. The hemolytic activity of the 
combination TB (100 μg ml−1)/EDTA (4 mg ml−1) as 
well as that of EDTA used alone up to16 mg ml−1, was 
also assessed following the same protocol.
Statistical analysis
Differences between the mean values of groups were eval-
uated by one-way analysis of variance (ANOVA) followed 
by Tukey-Kramer multiple comparison test or by Student’s 
t test. Data presented represent the mean ± the SEM of at 
least three independent experiments. A p value <0.05 was 
considered statistically significant.
Results
Activity of TB, alone and in combination with Cys 
and EDTA, in preventing biofilm formation of PIA-
positive and PIA-negative S. epidermidis strains
The MIC values of TB, Cys and EDTA against plank-
tonic S. epidermidis cells (two PIA-positive and two PIA-
negative strains) in the same experimental conditions used 
thereafter for the biofilm inhibition assay (ie stationary 
phase cells diluted 1:100 in BPM) were first determined 
(Table 2). In the case of TB, MIC values of 50 μg ml−1 
were recorded for the ATCC 35,984 and the SeVIC strains, 
while for the Se30 and SeBER strains the MIC values were 
25 μg ml−1. No growth inhibition was observed when the 
four S. epidermidis strains were incubated with Cys up to 
the concentration of 2,500-μΜ, while the MIC values of 
EDTA were 1,000 μg ml−1 for all the tested strains.
Table 2. MiC values of TB, Cys and EDTA in biofilm-like conditions.
avalues expressed in μg ml−1.
bvalues expressed in μM.
S. epidermidis strain TBa Cysb EDTAa
ATCC 35,984 50 > 2,500 1,000
Se30 25 > 2,500 1,000
SeBER 25 > 2,500 1,000
SeViC 50 > 2,500 1,000
Figure 1.  inhibitory effect of TB on biofilm formation by different 
clinical isolates of S. epidermidis. Bacterial cells of PiA-positive 
(ATCC; Se30) and PiA-negative (SeBER; SeViC) S. epidermidis 
strains were incubated in 96-well plates in the presence of 
different concentrations of TB. Cultures without peptide were 
used as positive controls. following incubation at 37°C for 24 h, 
the anti-biofilm effect was evaluated as a percentage of biofilm 
biomass reduction after CV staining (a) or as biofilm-associated 
viable bacteria counts (b).
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or 100 μg ml−1 TB was able to cause a statistically signif-
icant reduction in the Log10 number of CFU ml−1 of all 
tested strains, compared to the untreated control biofilms. 
At the higher peptide concentrations tested, the reduction 
in viable counts ranged from around 0.5 Log10 CFU ml−1 
for the ATCC 35,984 strain (80% reduction) to almost 2 
Log10 CFU ml−1 for the SeBER strain (99% reduction).
As bacteria within mature biofilms are less sensitive to 
antimicrobial agents than log-phase bacteria, the activity 
of TB on planktonic bacteria obtained by mechanical dis-
ruption of 24 h-old biofilms was evaluated. To this aim, 
bacteria dislodged from mature biofilms of S. epidermidis 
incubated in medium only. At a concentration of 50 μg 
ml−1 (~36-μM), the percentage inhibition was 100% for all 
four strains tested. These results correlated well with those 
obtained evaluating the number of biofilm-associated 
S. epidermidis viable cells (Figure 1b). In this case, at the 
concentration of 50  μg ml−1, around 3 Log10 reduction 
in the CFU number ml−1 was observed, compared to the 
bacteria incubated without the peptide, for all the four 
strains tested.
The ability of Cys and EDTA to potentiate the activity 
of TB against forming biofilms was assessed, as a 
percentage of biofilm biomass reduction, against one PIA-
positive (ATCC 35,984) and one PIA-negative (SeVIC) 
S. epidermidis strains chosen arbitrarily. When sub-
inhibitory concentrations of TB were used in combination 
with Cys against the ATCC 35,984 strain, the biofilm 
biomass reduction was statistically higher than that 
caused by Cys or TB used alone (Figure 2a). In particular, 
TB at the sub-inhibitory concentration of 12.5 μg ml−1 
(~9-μM) combined with 78-μM Cys caused more than 
an 80% reduction in the biomass of forming biofilms 
(Figure 2a). The effect of the combination was less evident 
against the PIA-negative strain SeVIC, even when the 
Cys concentration was increased to 300-μM (Figure 2b). 
Combining TB with EDTA did not cause any significant 
improvement in the ability of the peptide to inhibit biofilm 
formation of the two strains tested (data not shown).
Activity of TB alone and in combination with 
cysteine or EDTA in treating mature biofilms of PIA-
positive and PIA-negative S. epidermidis strains
The activity of TB in the treatment of established biofilms 
of S. epidermidis was evaluated as the number of viable 
biofilm-associated cells after incubation for 24 h with the 
peptide. As shown in Figure 3, at concentrations of 50 and/
Figure 2.  inhibitory effect of TB combined with cysteine on S. epidermidis biofilm formation. S. epidermidis ATCC 35,984 (a) and SeViC (b) 
cells were incubated with TB or cysteine (Cys) used alone and in combination. After incubation for 24 h at 37°C, the anti-biofilm effect 
was evaluated as a percentage of biofilm biomass reduction after CV staining. *p<0.05; ***p<0.001.
Figure 3.  Effect of TB on preformed biofilms of different clinical 
isolates of S. epidermidis. Bacterial cells of PiA-positive (ATCC; 
Se30) and PiA-negative (SeBER; SeViC) S. epidermidis strains were 
incubated in 96-well plates for 24  h to allow biofilm formation. 
After removing planktonic cells, established biofilms were treated 
with 50 and 100 μg ml−1 of TB for further 24 h and the anti-biofilm 
effect was evaluated as biofilm-embedded viable bacterial 
counts. Cultures without peptide were used as positive controls. 
***p<0.001.
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Interestingly, the bactericidal concentration of TB against 
bacteria harvested from biofilms was only 4-fold higher 
than that observed against log-phase bacteria (12.5  μg 
ml−1) (Figure 4).
Unlike what was observed with forming biofilms, 
no evident enhancement of TB activity against mature 
biofilms was observed when the peptide was combined 
with Cys (data not shown). In contrast, the ability of TB 
to reduce the CFU number of established biofilms was 
greatly enhanced when the peptide was combined with 
EDTA (Figure 5). Indeed, at a concentration of 100 μg 
ml−1, TB combined with EDTA (4  mg ml−1) caused > 
3 Log10 ml−1 reduction in the CFU number of the PIA-
positive S. epidermidis ATCC 35,984 strain (Figure 5a), 
compared to the control. An almost 1 Log10 ml−1 reduction 
in CFU number was instead observed when sub-inhib-
itory concentrations of both EDTA (0.03 mg ml−1) and 
TB (25  μg ml−1) were used to treat mature biofilms of 
the PIA-negative S. epidermidis SeVIC strain (Figure 5b).
Kinetics of the anti-biofilm effect and possible 
mechanism of the anti-biofilm action of the TB/EDTA 
combination against mature biofilms of  
S. epidermidis ATCC 35984
The kinetics of the anti-biofilm effect of the TB/
EDTA combination against established biofilms of the 
S. epidermidis ATCC 35,984 strain were then assessed. 
As shown in Figure 6, the enhancement of TB activity by 
EDTA was already evident after incubation for at both 2 
and 4 h, two time points at which EDTA alone had no 
effect. The reduction in the CFU number caused by the 
combination at 4 h was almost 2.5 Log10 ml−1 compared 
to EDTA and 1.5 Log10 ml−1 compared to TB used alone.
ATCC 35,984 were treated with different concentrations of 
TB in SPB with the addition of 1% TSB for 4 h. Thereafter, 
the number of bacteria resisting the treatment was deter-
mined and compared with that obtained from killing 
assays performed in parallel against log-phase bacteria. 
Figure 4 shows, for each experimental condition, the 
ratio between the Log10 CFU ml−1 of the control (bacte-
ria incubated in medium only) and the sample (bacteria 
incubated with different concentrations of TB). TB treat-
ment caused a reduction in the number of viable bac-
teria obtained from biofilms of about 1 Log10 (90%) at 
25 μg ml−1 and >3 Log10 (99.9%) at 50 μg ml−1 (Figure 4). 
Figure 4.   Bactericidal effect of TB against bacterial cells 
mechanically detached from mature biofilms of S. epidermidis 
ATCC 35,984 compared to mid-log phase cells. Planktonic bacteria 
harvested from exponentially growing cultures or from 24 h old 
biofilms were incubated for 4  h with different concentrations 
of TB in SPB with added 1% TSB at 37°C. The cells surviving the 
treatment were enumerated by Cfu count. Data are expressed as 
ratio between the log10 Cfu ml
−1 of untreated bacteria (control) 
and TB-treated bacteria (sample).
Figure 5.  Effect of TB combined with EDTA against preformed biofilms of S. epidermidis. 24 h-old biofilms of S. epidermidis ATCC 35,984 
(a) and SeViC (b) were exposed to TB or EDTA used alone or in combination for 24 h at 37°C. After incubation, the biofilm associated 
viable count (Cfu) was evaluated by plating the bacteria scraped from the wells. Control: bacteria incubated in medium only. *p<0.05; 
**p<0.01; ***p<0.001.
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ità
 di
 Pi
sa
] a
t 0
3:3
3 3
0 J
un
e 2
01
6 
794  G. MAISETTA ET AL.
greatly reduced not only in the biofilm, but also in the bio-
film supernatant, suggesting that the observed reduction 
in the viability of biofilm-embedded bacteria was due to 
a direct killing effect.
To investigate whether the therapeutic potential of 
TB combined with EDTA could be further improved by 
multiple exposures of mature biofilms to the combina-
tion, 24  h-old biofilms of S. epidermidis ATCC 35,984 
were exposed to TB/EDTA for 4 h, washed and exposed 
again to the same fresh combination for further 2 or 4 h. 
Compared to the 4-h exposure (Figure 6), no evident 
improvement in the therapeutic potential was observed 
by exposing mature S. epidermidis biofilms to the com-
bination for 4 h followed by 2 h (Figure 8). In contrast, 
two subsequent exposures, of 4 h each caused a further 
reduction in the CFU numbers compared to a single 4 h 
treatment (2.4 × 104 CFU ml−1 vs 2.1 × 105, respectively; 
P<0.05, Student’s t test), allowing the number of viable 
biofilm associated cells comparable to that obtained after 
a single exposure to TB+EDTA for 24 h (1.6×104 CFU 
ml−1) to be determined.
Evaluation of the activity of the TB/EDTA 
combination on mature biofilms of S. epidermidis 
by CLSM
The effect on mature biofilms of S. epidermidis ATCC 
35,984 of a double exposure to the TB/EDTA combina-
tion was evaluated by confocal fluorescence microscopy 
imaging (Figure 9). In agreement with the data obtained 
by the CFU count, 24 h-old biofilms treated twice with the 
TB/EDTA combination harbored high amounts of dead 
cells (stained red, Figure 9b), compared to the un-treated 
biofilms (Figure 9a). In addition, the biofilm architecture 
It has been reported recently that cationic peptides may 
degrade established biofilms by killing embedded bacteria 
or by causing the detachment of viable cells (Segev-Zarko 
et al. 2015). In order to gain insights into the possible 
mechanisms of the anti-biofilm action of the TB/EDTA 
combination against mature biofilms of S. epidermidis, 
CFU were enumerated both in the biofilms and in the 
biofilm-supernatants after treatment for 4 h. As shown in 
Figure 7, following the treatment, the number of CFU was 
Figure 6.  Kinetics of the anti-biofilm activity of TB in combination 
with EDTA on preformed biofilms of S. epidermidis ATCC 35,984. 
24 h-old biofilms were exposed to TB and EDTA alone and in 
combination. At different exposure times, the anti-biofilm effect 
was evaluated as biofilm-associated viable counts (Cfu). Control: 
bacteria incubated in medium without antimicrobial agents. 
*p<0.05; **p<0.01.
Figure 7.   Evaluation of the anti-biofilm mechanism of action of 
the TB/EDTA combination against mature biofilms of S. epidermidis 
ATCC 35,984. 24 h-old biofilms were exposed for 4 h to TB (100 μg 
ml−1) together with EDTA (4 mg ml−1) or to medium only (control). 
The viable count (Cfu) was then evaluated both in the biofilms 
and in the biofilm supernatants. ***p < 0.001.
Figure 8.   Anti-biofilm effect of two sequential exposures 
of established biofilms of S. epidermidis ATCC 35,984 to the 
combination TB/EDTA. 24 h-old biofilms were incubated for 4 h 
with TB (100 μg ml−1) in combination with EDTA (4 mg ml−1) and 
subsequently washed and exposed again for 2  h or 4  h to the 
same combination. **p<0.01; ***p<0.001.
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was greatly altered by the treatment, displaying large areas 
of disaggregation and a thickness reduction, compared to 
the control biofilms.
Testing the TB/EDTA combination as ‘lock therapy’ 
in an in vitro model of catheter-associated bacterial 
biofilms
Lock therapy is a technique used in clinical settings for 
the treatment of long-term intravascular catheter-related 
bacteremia (Fortún et al. 2006). It consists in the instil-
lation of high concentrations of an antimicrobial agent 
directly into the biofilm-containing catheter for exposure 
times sufficiently long to eradicate the biofilm. Due to the 
above reported ability of the TB/EDTA combination to 
treat established biofilms of S. epidermidis, the potential 
of such combination as lock solution for the salvage of 
infected catheters was evaluated. In order to mimic the 
lock therapy procedure in vitro, segments of silicone cath-
eters were incubated with suspensions of S. epidermidis 
ATCC 35,984 for 24 h to allow the formation of mature 
Figure 9.   Effect of TB/EDTA combination on S. epidermidis biofilm morphology and viability. (a) untreated 24  h-old biofilm of S. 
epidermidis ATCC 35,984; (b) 24 h-old biofilm of S. epidermidis ATCC 35,984, exposed to 100 μg ml−1 of TB and 4 mg ml−1 of EDTA for 4 h 
twice. Staining with green fluorescent labeled Syto 9 (488/500–540 nm) indicates live cells; staining with red fluorescent propidium 
iodide (Pi) (561/600–650 nm) indicates dead cells; Scale bar: 30 μm.
Figure 10.   Anti-biofilm effect of TB in combination with EDTA 
against biofilms of S. epidermidis ATCC 35,984 preformed on 
segments of silicone catheters. 24 h-old biofilms were exposed 
to EDTA and TB used alone and in combination for 4 h + 4 h. Cells 
were detached from biofilms by brief sonication and plated to 
enumerate Cfu. *p<0.05; ***p<0.001.
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The frog skin-derived TB belongs to a large family of 
small mildly cationic AMPs produced by the skin of Rana 
temporaria (Mangoni et al. 2016). It adopts a α-helical 
conformation in membrane mimicking environments 
and acts by perturbing the membrane of microbial cells 
without significant hemolytic or cytotoxic activity against 
eukaryotic cells (Mangoni 2006). The peptide was pre-
viously shown to display rapid killing effects against 
multi-drug-resistant, clinically relevant, bacterial path-
ogens and particularly against Gram-positive species 
(Mangoni et al. 2008). Recently it has been reported that 
TB, encapsulated in chitosan nanoparticles, is able to exert 
a strong and prolonged bactericidal effect against numer-
ous clinical isolates of S. epidermidis (Piras et al. 2015). 
Interestingly, it has been also demonstrated that the pep-
tide is able to penetrate eukaryotic cells, kill intracellular 
bacteria, and promote wound-healing (Di Grazia et al. 
2014). All these properties are important in view of a ther-
apeutic development of TB whose anti-biofilm properties 
have not been previously reported. In the present study, 
TB showed a striking ability to inhibit biofilm formation 
of different clinical isolates of S. epidermidis irrespective of 
whether the biofilm EPS was composed mainly of proteins 
or PIA. Unlike conventional antibiotics, that usually act 
against biofilms at concentrations much higher than their 
MIC, the inhibitory effect of TB was obtained at peptide 
concentrations close to the MIC values (25–50 μg ml−1) 
recorded for the different strains in biofilm-like condi-
tions, suggesting that such an effect was due to a direct 
killing activity of the peptide against biofilm-forming cells. 
Most conventional antibiotics work best against metaboli-
cally active bacterial cells (ie in exponential growth phase) 
as they target active cell processes such as protein, cell 
wall, or nucleic acids synthesis. Therefore, their activity is 
greatly reduced against biofilm cells that, overall, exhibit 
a low growth rate. TB mainly acts by causing membrane 
permeabilization (Rinaldi et al. 2001) and therefore it is 
highly likely to act also against metabolically inactive or 
slow growing cells.
Mature biofilms are known to be much more refrac-
tory than forming biofilms to antimicrobials including 
conventional antibiotics and AMPs. In the case of AMPs, 
this is mainly attributed to the multiple interactions that 
they may establish with components of the biofilm EPS 
(Batoni et al. 2016). These interactions may reduce the 
bioavailability of the peptides and lower their anti-bio-
film potential. When TB was assayed against both PIA-
dependent and protein-dependent preformed biofilms 
of S. epidermidis, a statistically significant reduction in 
the CFU number was observed for all tested strains at a 
concentration of 100 μg ml−1. In addition, TB was bacteri-
cidal against planktonic bacteria recovered by mechanical 
biofilms on the catheter surfaces. After washing, colonized 
catheter segments were exposed twice for 4 h each to TB 
(100 μg ml−1) in combination with EDTA (4 mg ml−1). As 
shown in Figure 10, biofilm-cell count levels compatible 
with those described for in vivo generated biofilms (Kite 
et al. 2004) were recovered from untreated catheters. In 
contrast, the number of viable cells harvested from cathe-
ters treated with the combination was around 3 Log10 ml−1 
lower than that obtained from the control catheters. The 
number of CFU ml−1 was so low (from 0 to 6, mean value 
2 CFU) that no visible bacterial growth was detected when 
replicates of treated catheters (n = 6) were placed in fresh 
bacterial growth medium for 72  h, suggesting that the 
antimicrobial lock treatment could significantly reduce 
or potentially eradicate catheter-associated biofilms of 
S. epidermidis.
Hemolytic activity of TB, the TB/EDTA combination, 
and EDTA
To evaluate the cytotoxic potential of TB, its ability to lyse 
human RBCs was tested in a standard hemolysis assay. 
No hemolytic activity was observed at TB concentrations 
ranging from 20 to 160  μg ml−1. A hemolytic effect of 
45% was observed at a TB concentration of 320  μg 
ml−1. Therefore, concentrations of TB active against 
S. epidermidis biofilms did not produce hemolysis on 
human erythrocytes (data not shown). Of note, no 
detectable hemolytic effect was also exhibited by the 
combination TB (100 μg ml−1)/EDTA (4 mg ml−1) or by 
EDTA alone, assayed up to 16 mg ml−1.
Discussion
The involvement of S. epidermidis biofilms in infec-
tions associated with indwelling medical devices and 
the possible development of antibiotic resistance by this 
bacterial species is receiving significant attention (Raad 
et al. 1998; Fey & Olson 2010). The potential of AMPs 
as a therapeutic alternative to conventional antibiotics 
to combat both increasing antibiotic resistance and the 
biofilm lifestyle is increasingly emerging (Park et al. 
2011; Strempel et al. 2015; Batoni et al. 2016). Indeed, 
AMP-activity against bacterial membranes is less spe-
cific than that of conventional antibiotics, thus lower-
ing the possibility of inducing bacterial resistance. In 
addition, AMPs display many properties suitable for an 
‘ideal’ anti-biofilm agent, not least the activity against 
metabolically inactive or poorly active cells, such as 
those in biofilms, circumventing the restriction of many 
traditional antibiotics that require actively growing 
bacterial cells to act (Batoni et al. 2016).
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biosynthesis might be less relevant, at least in the in vitro 
model employed.
Among the combinations tested on preformed biofilms, 
the TB (100 μg ml−1)/EDTA (4 mg ml−1) combination was 
the most promising. Hence, kinetics studies were performed 
in order to establish whether this combination could exert 
its anti-biofilm effect at earlier time points. Interestingly, a 
striking increase in the TB anti-biofilm effect was already 
evident after incubation for 4 h, an action time that can 
be considered rather short in comparison to conventional 
antibiotics. The mechanism of the anti-biofilm effect 
of the TB/EDTA combination on established biofilms 
was investigated by evaluating not only the viable count 
associated with the biofilm, but also that present in the 
biofilm supernatant. These experiments demonstrated that 
the reduction in the number of viable biofilm-embedded 
cells following TB/EDTA treatment was due to a real killing 
effect and not simply to the detachment of viable cells. 
This observation is relevant since, as previously outlined 
(Segev-Zarko et al. 2015), the detachment of live bacteria 
from a biofilm might be very detrimental as it promotes 
their spreading to the surrounding tissues or even to the 
bloodstream. The rapid effect exerted by the combination 
could be a consequence of the fast killing kinetics of TB 
(Mangoni et al. 2008) facilitated by the sequestration of 
cations by EDTA that, in turn, could destabilize the biofilm 
matrix and favor peptide penetration. The continuous drop 
in survival (Figure 6) could also be indicative of the ability 
of the combination to kill persister cells, metabolically 
inactive bacterial cells known to be highly represented 
in mature biofilms. This hypothesis is supported by 
preliminary data demonstrating that TB is able to kill 
experimentally generated persister cells of S. epidermidis 
(authors’ unpublished observation).
The anti-biofilm potential of the TB/EDTA combi-
nation could be further improved by exposing mature 
biofilms of S. epidermidis ATCC 35,984 to the combina-
tion for two consecutive periods of 4 h, suggesting that 
the second exposure may target bacteria localized in the 
deeper layers of the biofilm that resisted the first treat-
ment. The ability of the TB/EDTA combination to kill 
bacterial cells across the biofilm layers was demonstrated 
by CLSM analysis. Such analysis also revealed large areas 
of disaggregation in the biofilm architecture, supporting 
the hypothesis that EDTA may favor the penetration of TB 
into the biofilm, facilitating its interaction with bacterial 
cells and subsequent killing.
Among biomaterial-associated infections, those 
related to the use of central venous catheters (CVC) 
are particularly relevant. By several mechanisms, 
bacteria from the skin can migrate along the external 
and/or internal surface of the catheters, form biofilms, 
and represent the starting point of CVC-related 
disruption of preformed S. epidermidis biofilms, demon-
strating its potential to act on metabolically inactive cells. 
Such an effect was observed at a concentration of 50 μg 
ml−1, only 4-fold higher than the concentration needed 
to kill log-phase bacteria. This observation is relevant if 
it is considered that most conventional antibiotics exert 
a bactericidal effect towards biofilm-derived bacteria at 
concentrations much higher than their MBC values (up 
to 100-fold).
Due to the high antimicrobial resistance level of bacteria 
organized in biofilms and to the intrinsic heterogeneity 
of sessile bacterial communities, combination therapies 
are increasingly taken into consideration (Batoni et al. 
2016). Therefore, the possibility of improving the anti-
biofilm potential of TB by combining the peptide with 
Cys or EDTA against forming or mature biofilms of 
S. epidermidis was investigated.
TB in combination with Cys, but not with EDTA, 
was potentiated in inhibiting biofilm formation of S. 
epidermidis, although the inhibitory effect was more evident 
against the PIA-positive S. epidermidis ATCC 35,984 than 
the PIA-negative S. epidermidis SeVIC strain. The former 
strain was also more susceptible to the inhibitory effect 
of Cys alone than the latter strain (about a 40% reduction 
in biofilm biomass at a concentration of 78-μM for the 
ATCC 35,984 strain vs 300-μM for the SeVIC strain, 
Figure 2, P<0.05). These results are in agreement with the 
observation that sulfhydryl compounds are able to reduce 
the biosynthesis of EPS (eg PIA) by S. epidermidis (Wu et 
al. 2011). In turn, this could facilitate the direct interaction 
of the peptide with bacterial cells. Conversely, the lack of a 
synergistic effect with EDTA at the early stages of biofilm 
development may indicate that, in forming biofilms, the 
possible disaggregating effect of EDTA plays a minor role. 
A reverse effect was observed when TB was combined 
with Cys or EDTA against established biofilms of 
S. epidermidis. In this case, EDTA strongly potentiated 
the effect of TB against the PIA-positive S. epidermidis 
ATCC 35,984 strains. The ability of EDTA to destabilize 
the polysaccharides of the EPS may facilitate the diffusion 
of the peptide through the biofilm layers, improving its 
anti-biofilm potential. Although to a minor extent, EDTA 
potentiated the effect of TB also against the PIA-negative 
strain S. epidermidis SeVIC. A possible explanation 
is that polysaccharides other than PIA are possible 
components of biofilm EPS of PIA-negative strains of 
S. epidermidis (Spiliopoulou et al. 2012). In addition, 
possible disaggregating effects of EDTA could be due 
to sequestration of cations irrespective of the prevalent 
component constituting the EPS. Cys did not show any 
evident improving effect on TB activity against formed 
biofilms. It can be argued that once the biofilm is mature 
the inhibitory effect of Cys on extracellular matrix 
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antimicrobial agents (Beloin et al. 2014; Lebeaux et al. 
2015), the combination TB/EDTA was assayed against S. 
epidermidis biofilms established on segments of silicone 
catheters, simulating the antibiotic lock therapy.
The results obtained demonstrated that two consec-
utive exposures of 4 h each to 100 μg ml−1 of TB com-
bined with 4 mg ml−1 of EDTA substantially reduce the 
CFU count and potentially eradicate S. epidermidis bio-
films from the catheter surfaces. Of note, this effect was 
obtained at concentrations and exposure times lower 
than those reported in similar studies in the literature. 
For instance, minocycline tested at 3 mg ml−1 in com-
bination with 30 mg ml−1 EDTA was able to eradicate 
S. epidermidis biofilms after incubation for 24 h, while 
a combination of vancomycin (3 mg ml−1) and heparin 
(100 U ml−1) had no significant impact in reducing col-
onization of catheter segments by S. epidermidis (Raad 
et al. 2003). In another study, EDTA was tested alone at 
a concentration of 40 mg ml−1 for 21 h in in vitro models 
of catheter-associated biofilms (Percival et al. 2005). 
Recently, the antibiofilm effect of gentamicin, used at 
5 mg ml−1, was found to be increased by EDTA at 30 mg 
ml−1 against clinical isolates of S. epidermidis (Lebeaux 
et al. 2015). It is noteworthy that the TB/EDTA com-
bination at the eradicating concentration (100 μg ml−1 
TB, 4  mg ml−1 EDTA) was not hemolytic towards 
human erythrocytes. Thus, the in vitro data provide 
encouraging evidence for a potential application of the 
TB/EDTA combination in the lock therapy of catheters 
colonized with S. epidermidis biofilms. Studies in ani-
mal models of CVC-related infections will be needed to 
demonstrate the efficacy of such combination in vivo.
In conclusion, the present study offers a detailed 
analysis of the anti-biofilm potential of TB against 
clinical isolates of S. epidermidis. The peptide was 
demonstrated to inhibit the formation of both poly-
saccharide-dependent and protein-dependent biofilms 
of S. epidermidis and reduce, to a certain extent, the 
viable count of mature biofilms of both types. The 
anti-biofilm properties of TB could be greatly enhanced 
by combining the peptide with Cys or EDTA against 
forming or mature biofilms of S. epidermidis, respec-
tively. The anti-biofilm effect of the TB/EDTA combi-
nation against established biofilms was principally due 
to direct killing rather than to a mere disaggregating 
effect. Finally, the strong killing ability of the TB/EDTA 
combination was observed towards biofilms obtained 
on silicone catheters, suggesting the possible use of 
such a combination in the lock therapy of catheters 
colonized with S. epidermidis. The possible use of TB 
in combination with EDTA in the lock solution may 
reduce the risk of development of resistance compared 
to conventional antibiotics, while taking advantage of 
bloodstream infections (Yousif et al. 2015). Removal 
of large CVCs is not always feasible, and replacement 
is expensive and associated with a procedural 
risk for the patient. On the other hand, systemic 
antibiotic administration frequently fails to achieve 
sterilization. Among the numerous approaches used 
to prevent intraluminal contamination of catheters is 
the so-called lock therapy (Sousa et al. 2011; Justo & 
Bookstaver 2014). This consists in closing the catheter 
and exposing its internal surface to 1–2 ml of a solution 
containing a highly concentrated antibiotic (up to 1,000 
times the MIC) in order to eradicate the biofilm and 
an anticoagulant to prevent thrombosis (Sousa et al. 
2011; Justo & Bookstaver 2014). After 12–24 h, the lock 
solution is removed, but repetition of the treatment 
at 24  h intervals for up to 15-days might be needed 
for complete eradication. Although clinical guidelines 
recommend the lock therapy in non-complicated cases 
of long-term catheter stay, the actual lock therapies 
have several limits regarding both the antimicrobial and 
the anticoagulant agents (Mermel et al. 2009; Justo & 
Bookstaver 2014). Among the major limits, there is the 
need to use high concentrations of antibiotics that may 
cause systemic toxicity and/or promote the selection 
and diffusion of multidrug resistant strains. Regarding 
the anticoagulant agent, heparin is frequently used, 
but it has several disadvantages (McIntyre et al. 2004). 
It causes the development of thrombosis mediated 
by anti-heparin antibodies and, at clinical relevant 
concentrations, it may enhance biofilm formation 
(Shanks et al. 2006). Moreover, locking of long-term 
intravenous catheters reduces their availability for 
several days and to date no antibiotics singularly used 
are able to eradicate CVC-associated bacterial biofilms 
in an acceptable time-span. For all these reasons, 
there is a pressing need to identify more effective lock 
solutions to eradicate intraluminal biofilms and reduce 
the time during which the catheter is unavailable. In 
this regard, EDTA used alone or in combination with 
antibiotics has recently emerged as a promising adjuvant 
of antimicrobial catheter lock solutions due to its dual 
anticoagulant and anti-biofilm activity (Chauhan et al. 
2012). In the present study, it was demonstrated that 
TB in combination with EDTA could greatly reduce the 
viable count of S. epidermidis biofilms grown on the 
surface of polystyrene plates and kill bacteria released 
from the biofilm. These results suggest a possible use 
of the TB/EDTA combination for the lock therapy of 
catheters infected with S. epidermidis, one of the most 
common bacterial species involved in the colonization 
of this type of medical devices. As the characteristics 
of the surface used for biofilm formation might 
greatly influence the phenotype of tolerance towards 
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